[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Libby B, Chao D, Schneider BF: Non-surgical treatment of primary female urethral cancer. Rare Tumors; 2010;2(3):e55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-surgical treatment of primary female urethral cancer.
  • Primary carcinomas of the female urethra are extremely rare, with an annual incidence of less than ten in one million.
  • However, there have been several case reports demonstrating the efficacy of chemoradiation in the treatment of female urethral cancer.
  • In this report we present two cases of female primary urethral adenocarcinoma that were treated by concomitant chemotherapy and external beam radiotherapy, followed by interstitial brachytherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139970.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994528
  • [Keywords] NOTNLM ; high-dose rate / low-dose rate. / urethral cancer
  •  go-up   go-down


2. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Magnetic resonance imaging showed a tumor surrounding the urethra, which invaded to the vesical triangle and the anterior vaginal wall.
  • Pathological examinations of the transurethral and transvaginal needle biopsy specimen suggested mucinous adenocarcinoma.
  • First, the patient received local chemoradiotherapy and systemic chemotherapy using a fluoropyrimidine drug TS-1 and cisplatin.
  • The tumor markers declined to within normal limits after this preoperative therapy.
  • Histopathological examination of the surgical specimen showed mutinous adenocarcinoma invading to the vesical triangle and the anterior vaginal wall.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Awakura Y, Nonomura M, Itoh N, Maeno A, Fukuyama T: Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy. Int J Urol; 2003 May;10(5):281-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy.
  • The diagnosis by urethroscopy and radiological evaluation was localized urethral diverticular tumor.
  • Pathological examination of the biopsy specimen revealed adenocarcinoma.
  • The patient received two courses of intra-arterial and systemic chemotherapy using cisplatin, 5-fluorouracil and leucovorin, followed by radiation to the urethra.
  • The tumor shrunk markedly after chemotherapy.
  • Adenocarcinoma of the female urethral diverticulum is rare and has been treated by surgery and/or radiation.
  • The present case is the first case of it being treated by multimodality therapy including chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diverticulum / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694472.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Segura Huerta A, Molina Saera J, Palomar Abad L, Pellín Ariño L, Guerrero Zotano A, Calderero Aragón V: [Advanced urethral carcinoma. Which is the best management of a infrequent disease?]. Actas Urol Esp; 2004 Jan;28(1):57-61
Genetic Alliance. consumer health - Best Vitelliform Macular Dystrophy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced urethral carcinoma. Which is the best management of a infrequent disease?].
  • Urethral cancer is an uncommon tumor (<0.1% of all genitourinary neoplasms).
  • Most of them are squamous carcinoma, adenocarcinomas are about 5% of all urethral cancer.
  • Surgery is the only curative treatment.
  • Chemotherapy (CT) and radiotherapy (RT) must be used in patients in which surgery is not possible.
  • Due to the low incidence of this neoplasm is not well established the best therapeutic approach.
  • We present the case of a female (35 years old) with a diagnosis of urethral adenocarcinoma.
  • Surgery was impossible and the patient received chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Urethral Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15046483.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Soares MJ, Neves T, Covita A, Monteiro P, Canhoto A, Nogueira R, Barreto JL, Mendonça JC, Maya M, Monteiro H: [Bladder adenocarcinoma. Case report]. Arch Esp Urol; 2008 Sep;61(7):828-31
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder adenocarcinoma. Case report].
  • [Transliterated title] Adenocarcinoma vesical. Aportación de un caso clínico.
  • OBJECTIVE: Primary bladder adenocarcinoma is a rare entity.
  • Trans-urethral resection revealed an invasive adenocarcinoma.
  • The bladder specimen showed primary bladder adenocarcinoma, pT3aNO.
  • CONCLUSION: Primary bladder adenocarcinoma is rare.
  • Unlike urothelial carcinoma, it responds poorly to chemotherapy or radiotherapy Radical Cistectomy offer the best chance of long-term survival.
  • [MeSH-major] Adenocarcinoma. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972921.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


6. Ahmad NA, Memon A, Hussainy A: Abdominoperineal excision of male lower urinary tract for synchronous adenocarcinoma of urethra and urinary bladder. Urology; 2005 Mar;65(3):591
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal excision of male lower urinary tract for synchronous adenocarcinoma of urethra and urinary bladder.
  • Urethral adenocarcinoma is the least common histologic subtype of a rare primary carcinoma of the male urethra.
  • This report is of a 40-year-old morbidly obese man with synchronous adenocarcinoma of the bulbar urethra and bladder, treated surgically by en bloc abdominoperineal penoprostatocystectomy.
  • The pleural recurrence, after a disease-free period of 2 years, responded well to platinum-docetaxel-based systemic chemotherapy.
  • Synchronous occurrence of adenocarcinoma of the urethra and bladder has not been previously reported.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasms, Multiple Primary / surgery. Urethral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780385.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


7. Koizumi T, Bando S, Kanda K, Inai T: [Two cases of primary female urethral cancer]. Nihon Hinyokika Gakkai Zasshi; 2007 Sep;98(6):790-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of primary female urethral cancer].
  • Herein, we report two cases of female urethral cancer.
  • Magnetic resonance imaging (MRI) revealed a urethral tumor in both cases.
  • Histopathological examination of transperineal biopsy specimens from both patients suggested clear cell adenocarcinoma in case 1 and squamous cell carcinoma in case 2.
  • With reference to case 1, obturator lymph node metastases were observed during surgery, and treatment comprised combined radiotherapy to 60 Gy and chemotherapy with 5-fluorouracil and cisplatin following surgery.
  • However, metastases appeared in the lung 6 months after initial treatment and she died 20 months after surgery.
  • The same combined treatment was performed and a complete response was obtained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Urethral cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929463.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


8. Morikawa H, Cho M, Takada S, Fujimoto K, Uemura H, Ozono S, Hirao Y, Natsume O: [A case of primary transitional cell carcinoma of the prostate]. Hinyokika Kiyo; 2003 Jun;49(6):357-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological diagnosis of prostate biopsy specimen was transitional cell carcinoma with grade 3 malignancy and negative staining for PSA.
  • Endoscopic examination showed a normal appearance of bladder and prostatic urethral epithelium.
  • However, immunostaining for PSA revealed that the cervical lymph node specimen resected before was moderately differentiated adenocarcinoma of prostate.
  • Endocrine therapy (goserelin acetate depot, bicalutamide) and systemic chemotherapy (methotrexate, epirubicin, cisplatin) were performed combined with irradiation to right ischium metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Fatal Outcome. Humans. Male. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894737.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 11
  •  go-up   go-down


9. Noorani S, Rao AR, Callaghan PS: Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma. Int Urol Nephrol; 2007;39(3):837-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral metastasis: an uncommon presentation of a colonic adenocarcinoma.
  • INTRODUCTION: Metastases to the urethra are a rare clinical entity.
  • In this report, however we describe a case of urethral metastases from a colonic cancer origin where the urethral lesion was the presenting symptom.
  • CASE REPORT: A 69-year-old woman presented with a swelling at the urethral opening.
  • Per vaginal examination revealed a hard tender lesion situated at the external urethral meatus with contact bleeding.
  • Excision biopsy revealed adenocarcinoma.
  • Subsequent investigations revealed that the patient did indeed have a sigmoid adenocarcinoma and underwent chemotherapy with a view to anterior resection and pelvic exenteration.
  • DISCUSSION: Metastases to the urethra are rare.
  • Treatment options have to be individualised to the extent of the disease and the symptoms of the patient.
  • Atypical presentations of urethral lesions should be viewed with suspicion.
  • A biopsy of the lesion is the only way of confirming diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Sigmoid Neoplasms / pathology. Urethral Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Apr;163(4):1245-6 [10737510.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1057-63 [12204054.001]
  • [Cites] ANZ J Surg. 2004 Oct;74(10):925-7 [15456455.001]
  • [Cites] Arch Surg. 1973 Dec;107(6):906-8 [4751838.001]
  • [Cites] Int Braz J Urol. 2003 Sep-Oct;29(5):431-3 [15745589.001]
  • [Cites] Indian J Cancer. 1994 Mar;31(1):31-3 [8063334.001]
  • (PMID = 17318345.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Benchekroun A, Nouini Y, Zannoud M, Kasmaoui el H, Jira H, el Alj HA: [Ureteral adenocarcinoma in men: a case report]. Ann Urol (Paris); 2003 Jun;37(3):131-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureteral adenocarcinoma in men: a case report].
  • Adenocarcinoma of urethra is a rare tumour, which occurs more often in female than in male.
  • The localizations on bulbomenbranous urethra, most frequent, have worse prognostic than those of penile urethra.
  • Because of scarcity of these tumours there is not therapeutic consensus.
  • The treatment is based on the tripod surgery, more or less mutilating, chemotherapy and radiotherapy associated or managed in a separate way.
  • We report the case of a young patient with adenocarcinoma of the posterior urethra treated by a protocol of radio-chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / pathology
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Male

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872605.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Hamasaki T, Kondo Y, Ogata Y, Yoshida K, Kimura G, Shimizu H, Nishimura T: Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol; 2010 Feb;15(1):109-11
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.
  • Pathological examination diagnosed poorly differentiated urothelial carcinoma of the urethra with broad prostatic permeation.
  • Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed.
  • Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m(2), ifosfamide 1.2 g/m(2) and docetaxel 70 mg/m(2) (PIT) was considered.
  • After chemotherapy, CT showed complete response (CR) of all lymph nodes.
  • Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / secondary. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Prostatectomy. Prostatic Hyperplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 Nov;48(5):703-10 [8911513.001]
  • [Cites] Am J Clin Pathol. 1963 Aug;40:183-9 [14060023.001]
  • [Cites] J Urol. 1973 Mar;109(3):457-60 [4348139.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Hinyokika Kiyo. 2000 Jul;46(7):495-8 [10965459.001]
  • [Cites] Urology. 1984 Dec;24(6):544-9 [6506393.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Br J Urol. 1979 Dec;51(6):575-8 [534844.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):50-61 [17280908.001]
  • [Cites] Hinyokika Kiyo. 1970 Apr;16(4):157-61 [5463380.001]
  • (PMID = 20087614.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Tiguert R, Ravery V, Madjar S, Gousse AE: [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra]. Prog Urol; 2001 Feb;11(1):70-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra].
  • The authors report a case of primary clear cell cancer of the urethra in a woman presenting with acute urinary retention.
  • The diagnosis was based on cystoscopy and confirmed by histological examination of urethral biopsies.
  • Treatment consisted of urethrocystectomy with creation of an "Indiana pouch".
  • She was treated with 3 courses of chemotherapy (mitomycin and 5-fluorouracil) combined with radiotherapy.
  • This case report emphasizes the rarity of this histological type and describes the management of urinary retention in a woman when an underlying specific disease is suspected.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296650.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • We reviewed 53 patients (mean age 63 years) who underwent partial urethrectomy (n = 26) or radical extirpation (n = 27) for primary female urethral cancer from 1948 through 1999.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • The predominant carcinomas were squamous cell (n = 21), transitional cell (TCC) (n = 15), and adenocarcinoma (n = 14).
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • Of patients undergoing partial urethrectomy for pT1-3 tumors, 6/27 (22%) had urethral recurrence.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ouzaid I, Hermieu JF, Dominique S, Fernandez P, Choudat L, Ravery V: Management of adenocarcinoma of the female urethra: case report and brief review. Can J Urol; 2010 Oct;17(5):5404-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adenocarcinoma of the female urethra: case report and brief review.
  • INTRODUCTION: We present a case of a differentiated adenocarcinoma of the female urethra, which caused dysuria and voiding dysfunction.
  • RESULTS: An ultrasound-guided biopsy showed a urethral carcinoma.
  • CONCLUSION: Urethral carcinoma is a rare malignancy.
  • A biopsy is necessary to make a diagnosis.
  • Advanced disease should be treated with a multimodality of options including neoadjuvant radiotherapy given concomitantly with chemotherapy followed by surgery.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Pelvic Exenteration. Treatment Outcome. Urologic Surgical Procedures / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974039.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  •  go-up   go-down


15. Bakkali H, Benjaafar N, Mansouri A, Errihani H, Kettani F, Benchekroun A, El Gueddari Bel K: [Primary adenocarcinoma of the male urethra. A case report]. Cancer Radiother; 2002 Dec;6(6):358-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the male urethra. A case report].
  • Primary adenocarcinoma of the male urethra is very uncommon, accounts for 5% of primary urethral cancers.
  • All types of urethral carcinomas account for less than 1% of urinary malignancies in man.
  • The prognosis remains poor despite the wide surgical treatment.
  • The place of chemotherapy combined with radiotherapy must be defined by other studies.
  • We report a case of primary locally advanced adenocarcinoma arising in the bulbo-membranous urethra.
  • He was treated by combined external beam radiotherapy (total dose 67Gy) and chemotherapy (Cisplatinum).
  • A marked reduction of tumor volume has been noted but the patient died because of the appearance of bone metastasis which failed to the systemic therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504773.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Doddamani D, Ansari MS, Gupta NP, Aron M, Singh I, Datta Gupta S: Mesonephroid adenocarcinoma of the bladder and urethra: a case report. Int Urogynecol J Pelvic Floor Dysfunct; 2002;13(1):47-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephroid adenocarcinoma of the bladder and urethra: a case report.
  • Mesonephric or mesonephroid adenocarcinoma of the bladder may be a malignant form of nephrogenic adenoma or nephroid metaplasia.
  • We report another case of mesonephroid adenocarcinoma of the bladder and urethra which was treated with transurethral resection and subsequent chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Mesoderm / pathology. Nephrons / pathology. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Female. Humans. Methotrexate / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999207.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Nagano M, Hasui Y, Ide H, Itoi T, Takehara T, Osada Y: Primary adenocarcinoma arising from a paraurethral cyst in a female patient. Urol Int; 2002;69(3):244-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma arising from a paraurethral cyst in a female patient.
  • A very rare case of primary adenocarcinoma arising from a paraurethral cyst in a 63-year-old woman is reported.
  • Initially she was diagnosed as having a simple paraurethral cyst because of absent communication with the urethra.
  • The resected paraurethral cyst was histologically associated with adenocarcinoma.
  • We also performed chemotherapy composed of methotrexate, vinblastine, Adriamycin and cisplatin because of lymph node metastasis.
  • Our treatment, however, was not effective and the patient died of systemic metastases.
  • [MeSH-major] Adenocarcinoma / pathology. Cysts / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Combined Modality Therapy / methods. Fatal Outcome. Female. Humans. Middle Aged. Ultrasonography, Doppler. Urethral Diseases / pathology. Urogenital Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12372897.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Kurosaka S, Irie A, Mizoguchi H, Okuno N, Iwabuchi K, Baba S: Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy. Int J Clin Oncol; 2005 Oct;10(5):362-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy.
  • The tumor seemed to have arisen from the bladder or urethra, and bilateral iliac lymphadenopathy was seen.
  • Her urethral mucosa looked intact according to the results of cystourethroscopy.
  • Histopathological examination of the biopsy specimens showed clear-cell adenocarcinoma.
  • Macroscopically, the tumor had arisen from the trigone of the bladder, and histopathological examination of the tumor revealed adenocarcinoma exhibiting solid clear cells with glandular and papillary patterns.
  • Postoperatively, three courses of systemic combination chemotherapy with 5-fluouracil (FU) and cisplatin, along with a total of 45 Gy of irradiation during the second course of chemotherapy, were conducted.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Cystectomy. Female. Humans. Lymph Node Excision. Middle Aged. Pelvis. Urethra / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2002 Aug;9(8):467-9 [12225345.001]
  • [Cites] Urol Int. 2003;71(2):228-30 [12890970.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(1):13-6 [8750509.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):39-48 [11121861.001]
  • [Cites] Mod Pathol. 1993 Mar;6(2):225-8 [8483895.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1984 Mar;23(3):303-4 [6199882.001]
  • [Cites] J Urol. 1990 Jan;143(1):122-5 [2294240.001]
  • (PMID = 16247666.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Chvapil M, Kielar F, Liska F, Silhankova A, Brendel K: Synthesis and evaluation of long-acting D-penicillamine derivatives. Connect Tissue Res; 2005;46(4-5):242-50
Hazardous Substances Data Bank. (D)-PENICILLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study extends the use of two lathyrogens, ss-aminopropionitrile (BAPN) and D-penicillamine (DPA) from daily systemic or local-topical administration to long-time acting agents.
  • This was achieved by converting the hydrophilic drugs into lipophilic derivatives.
  • During neutralization in vitro or in vivo by tissue fluid, an oily substance is formed that elutes from a hydrogel polymer at a much slower rate than hydroplilic DPA itself.
  • Both agents injected into the breast adenocarcinoma in Fisher rats significantly inhibited tumor growth without any signs of local or systemic toxicity.
  • We conclude that these lipophilic lathyrogens with prolonged effectiveness are suitable in the treatment of pathologies, consisting of excessively cross-linked or deposited collagen (fibrotic adhesions, strictures, stenosis, and scar contractures) and in the treatment of single, solitary tumors, malignant and benign.
  • [MeSH-major] Aminopropionitrile / analysis. Aminopropionitrile / chemical synthesis. Cicatrix, Hypertrophic / drug therapy. Connective Tissue Diseases / drug therapy. Neoplasms / drug therapy. Penicillamine / analogs & derivatives. Penicillamine / chemical synthesis
  • [MeSH-minor] Adenocarcinoma / drug therapy. Alcohols / chemistry. Animals. Collagen / drug effects. Collagen / metabolism. Constriction, Pathologic / drug therapy. Constriction, Pathologic / metabolism. Constriction, Pathologic / physiopathology. Esterification. Female. Hexanols / chemistry. Mammary Neoplasms, Experimental / drug therapy. Molecular Structure. Rats. Rats, Inbred F344. Tissue Adhesions / drug therapy. Tissue Adhesions / metabolism. Tissue Adhesions / physiopathology. Treatment Outcome. Urethral Stricture / drug therapy. Urethral Stricture / metabolism. Urethral Stricture / physiopathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Connective Tissue Disorders.
  • Hazardous Substances Data Bank. BETA-AMINOPROPIONITRILE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546828.001).
  • [ISSN] 0300-8207
  • [Journal-full-title] Connective tissue research
  • [ISO-abbreviation] Connect. Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alcohols; 0 / Hexanols; 151-18-8 / Aminopropionitrile; 9007-34-5 / Collagen; GNN1DV99GX / Penicillamine
  •  go-up   go-down


20. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW: Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology; 2002 Oct;60(4):650-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
  • OBJECTIVES: To evaluate the influence of prophylactic versus therapeutic alpha-blockers on urinary morbidity after permanent prostate brachytherapy.
  • Multiple clinical and treatment parameters were evaluated to identify the factors associated with acute urinary morbidity.
  • In 142 patients, an alpha-blocker was initiated before implantation and continued at least until the International Prostate Symptom Score (IPSS) returned to baseline levels; 92 patients either did not receive an alpha-blocker or received a therapeutic alpha-blocker after implantation because of urinary obstructive symptoms.
  • The clinical and treatment parameters evaluated for urinary morbidity included prophylactic versus therapeutic alpha-blockers, age, preimplant IPSS, ultrasound volume, use of neoadjuvant hormones, use of supplemental external beam radiotherapy, isotope, urethral dose, and multiple dosimetric quality indicators (minimal dose received by 90% of the prostate gland and percentage of prostate volume receiving 100% or 200% of the prescribed minimal peripheral dose).
  • RESULTS: In both the prophylactic and the therapeutic cohorts, the IPSS peaked 1 month after implantation.
  • Of the 125 patients receiving prophylactic alpha-blockers, 102 (81.2%) remained medication dependent at the conclusion of the study, and 140 (78.2%) of 179 patients receiving alpha-blockers other than for hypertensive purposes did so.
  • Cox regression analysis revealed that only the prophylactic use of alpha-blockers and the difference between the preimplant IPSS and the 1-month IPSS were predictive of the time to return to the referent zone.
  • CONCLUSIONS: Prophylactic use of alpha-blockers results in significantly less urinary morbidity than either the absence or therapeutic use of alpha-blockers.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adrenergic alpha-Antagonists / therapeutic use. Brachytherapy / adverse effects. Postoperative Complications / drug therapy. Postoperative Complications / prevention & control. Prazosin / analogs & derivatives. Prostatic Neoplasms / radiotherapy. Urination Disorders / drug therapy. Urination Disorders / prevention & control
  • [MeSH-minor] Biopsy. Doxazosin / therapeutic use. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use. Male. Palladium / therapeutic use. Prostate / pathology. Prostate-Specific Antigen / blood. Radioisotopes / therapeutic use. Radiotherapy, Conformal. Sulfonamides / therapeutic use. Treatment Outcome. Urinary Retention / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12385927.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Iodine Radioisotopes; 0 / Radioisotopes; 0 / Sulfonamides; 5TWQ1V240M / Palladium; 8L5014XET7 / Terazosin; EC 3.4.21.77 / Prostate-Specific Antigen; G3P28OML5I / tamsulosin; NW1291F1W8 / Doxazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


21. Izawa JI, Perrotte P, Greene GF, Scott S, Levy L, McGuire E, Madsen L, von Eschenbach AC, Pisters LL: Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol; 2001 Mar;165(3):867-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated certain variables on univariate and multivariate analysis as predictors of a positive biopsy after cryotherapy, including the type of previous therapy, tumor stage and grade at initial diagnosis, prostate volume, pre-cryotherapy prostate specific antigen (PSA), number of positive biopsy cores before cryotherapy, PSA nadir after cryotherapy, stage and grade of local recurrence, number of cryoprobes, number of freeze-thaw cycles and use of a urethral warming catheter during cryotherapy.
  • Variables associated with a positive biopsy on univariate analysis were initial stage, precryotherapy PSA, PSA nadir after cryotherapy, number of cryoprobes, number of freeze-thaw cycles and a history of chemotherapy (p = 0.005, 0.027, 0.001, 0.009, 0.018 and 0.008, respectively).
  • Therefore, they are better candidates for salvage cryotherapy for locally recurrent prostate adenocarcinoma after external beam radiotherapy.
  • [MeSH-minor] Biopsy. Humans. Male. Multivariate Analysis. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176488.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


22. Jin B, Pickens A, Shah MB, Turrisi A, Saleh H: Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case. Diagn Cytopathol; 2010 Dec;38(12):925-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other malignancies include adenocarcinoma, melanoma, lymphoma, and very rarely, neuroendocrine carcinoma/small-cell carcinoma.
  • Subsequent clinical workup showed that the patient also had numerous metastatic nodules in the bilateral lungs and a vaginal-urethral fistula caused by the tumor.
  • The patient underwent palliative radiation of pelvis for local pain control and then chemotherapy.
  • Although the vaginal tumor increased in size even after radiation, her symptoms were under control and she was doing well for a short period of time.
  • The patient is still alive but developed brain metastasis a year later after initial diagnosis.
  • Despite its rarity, large cell neuroendocrine cell carcinoma should be included in the differential diagnosis when cytomorphology shows features suggestive of neuroendocrine differentiation.
  • [MeSH-minor] Antigens, CD56 / metabolism. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20222107.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down






Advertisement